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ABstrACt
Hedgehog signaling has been implicated in the development of several human 
cancers, including small cell lung carcinomas, medulloblastomas, basal cell carcinomas, 
and digestive tract tumors. Elevated levels of pathway components are observed in 
pancreatic ductal adenocarcinoma (PDAC) precursor lesions, and these levels increase 
further as lesions progress to more advanced stages. Yet the mechanisms by which 
hedgehog signaling contributes to pancreatic tumorigenesis were poorly understood. 
We recently published results showing that activated hedgehog signaling enhances the 
proliferation and survival of pancreatic duct epithelial cells, the presumptive target cells 
for PDAC development. We also demonstrated that sonic hedgehog (Shh) expression, in 
cooperation with loss of the Trp53 and Ink4a/Arf tumor suppressor loci, was sufficient to 
initiate the formation of early pancreatic lesions. Furthermore, Shh signaling enhanced 
K‑Ras‑mediated pancreatic tumorigenesis and reduced the dependence of tumor cells 
on the sustained activation of Ras‑stimulated signaling pathways. Here we discuss the 
significance of these findings and the implications for therapy.
IntroduCtIon
The hedgehog signaling pathway is vital for embryonic development, particularly 
gastrointestinal patterning.1,2 Shh is also active in a subset of cells in mature organs 
and may play a role in maintaining stem cell number and accurate patterning in the 
epithelia of the lungs, the skin3 and the digestive tract.4,5 Deregulation of hedgehog 
signaling has also been observed in several human cancers, including small cell lung 
carcinomas, medulloblastomas, basal cell carcinomas and digestive tract tumors.4-7 In fact, 
activation of the hedgehog signaling pathway occurs in a majority of pancreatic ductal 
adenocarcinomas.4,5
There are three mammalian hedgehog genes: Sonic (Shh), Indian (Ihh) and Desert 
(Dhh), all of which encode signaling molecules that undergo autocatalytic cleavage and 
double lipid modification to generate an active ligand.2,8 In the absence of hedgehog 
ligand, the hedgehog receptors, Patched1 and Patched2 (hereafter denoted as Ptch), are 
involved in repression of the hedgehog signaling molecule Smoothened (Smo).9 Upon 
ligand binding, Smo is released from inhibition, providing a signal for the dissociation of 
Gli transcription factors from an inhibitory complex that includes the serine/threonine 
protein kinase Fused (Fu), and Suppressor of Fused [Su (Fu)].9 The Gli transcription 
factors translocate to the nucleus where they regulate the transcription of hedgehog 
responsive genes including Ptch and Gli itself.10 Also among the reported targets of 
hedgehog signaling are the genes encoding the cell cycle regulators Cyclin D1, N-Myc and 
p21, and the Wnt proteins.8,11,12
Pancreatic cancer is a very aggressive malignancy, exemplified by a five year survival rate 
of 5% and median survival of less than six months.13,14 Approximately 30,000 Americans 
are diagnosed with pancreatic cancer each year, and an equal number die from the disease, 
making this malignancy the fourth leading cause of cancer-related deaths in the United 
States.14 Pancreatic cancers arise from the three major cell types within the organ - acinar 
cells, endocrine cells and duct epithelial cells, however pancreatic ductal adenocarcinoma 
(PDAC) accounts for more than 85% of all cases.15 The putative target cells of PDAC 
are the duct epithelial cells, although the exact nature of the progenitor cell has not 
been identified.16 PDAC arises from precursor lesions called pancreatic intraepithelial 
neoplasms (PanINs). These lesions sequentially acquire specific genetic alterations during 
progression towards malignancy, including activation of K-Ras and loss of Ink4a in PanIN 
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1 and 2, loss of p53 in PanIN 2–3, and loss of Smad4 
in PanIN 3.17 PanIN lesions are also characterized by 
specific histological changes. These include conver-
sion of the normal cuboidal duct epithelial cells 
to a columnar phenotype, formation of papillary 
architecture and mucin accumulation in PanIN 1, 
loss of polarity and appearance of atypical nuclei 
in PanIN 2, and luminal budding and increased 
mitoses in PanIN 3.17,18
Intriguingly, Shh is excluded from the devel-
oping pancreas, as well as the mature organ,19 yet 
is expressed in early PanIN lesions, with increasing 
levels as lesions progress to invasive PDAC.5 
Ectopic expression of Shh under the control of 
the Pdx-1 promoter, active in pancreas progenitor 
cells, leads to ductal abnormalities accompanied by 
mutations in K-Ras - an early event in PDAC devel-
opment.5 Shh signaling is also active in a majority of 
pancreatic cancer cell lines, and inhibition of 
hedgehog signaling blocks proliferation and induces 
apoptosis in a subset of these cell lines, both in 
vitro and in vivo.5 Further, a study of the gene 
expression profiles of early PanIN lesions revealed 
upregulation of several foregut markers, many of 
which were also upregulated in Gli1 overexpressing 
human pancreatic duct epithelial cells.20 Thus, there 
is growing evidence to suggest that activated Shh 
signaling is a critical early mediator of pancreatic 
cancer development.
shh ContrIButes to PAnCreAtIC tuMor 
InItIAtIon
Given this information we investigated the mechanisms by which 
Shh contributes to pancreatic tumorigenesis. We found that Shh 
expression enhances the proliferation of pancreatic duct epithelial 
cells, potentially through the transcriptional regulation of the cell 
cycle regulators cyclin D1 and p21.21 We also observed increased 
phosphorylation of the signaling molecules Akt and Erk1/2 in cells 
with active Shh signaling.21 Activation of the PI3K/Akt pathway 
is implicated in enhancing cell survival, while Erk1/2 activation is 
associated with cell proliferation. Collectively, these data indicate 
that Shh stimulates proliferation of PDECs through the regulation 
of multiple molecules. We also found that in addition to providing a 
proliferative stimulus, Shh expression confers protection from death 
receptor-dependent, caspase 8-mediated apoptosis, at least partially 
through post-transcriptional activation of Bcl-2 and Bcl-XL.
21 
Orthotopic transplantation of PDECs with constitutive activation of 
Shh signaling and loss of the Ink4a/Arf or Trp53 tumor suppressor 
loci, was sufficient to induce the formation of early pancreatic ductal 
lesions, but not pancreatic carcinomas.21 This result is consistent 
with previous findings that Shh pathway activation is present within 
early PanIN lesions, and supports a role for the Shh pathway in 
PDAC initiation.
It remains unknown how Shh signaling activates the MAPK and 
Akt/mTOR pathways in PDECs, however, previous studies have 
demonstrated that PDGF,22-24 and IGF signaling components24 
are targets of Shh signaling. Thus, one likely possibility is that Shh 
stimulates receptor tyrosine kinase signaling, resulting in activation 
of MAPK and PI3K/Akt/mTOR pathways. Interestingly, we, and 
others, have shown that expression of activated Gli molecules does 
not result in the stimulation of Erk.21,25 Intriguingly, while we did 
not observe activation of Akt in PDECs expressing an activated Gli1 
molecule, Pasca di Magliano et al 23 observed Akt phosphorylation in 
pancreatic tumors induced by an activated Gli2 allele. This discrep-
ancy may reflect functional differences between Gli1 and Gli2, or 
it may indicate a requirement for PI3K/Akt signaling in pancreatic 
tumor development, which occurred via a Gli2-independent mecha-
nism. Analysis of PDECs from mice expressing the activated Gli2 
allele might address this question. Thus, the data indicate that Shh 
may signal at least in part through Gli-independent mechanisms to 
activate Akt and Erk.
shh And FAs sIgnALIng In PAnCreAtIC CAnCer
In order to progress, pancreatic tumors must escape immune clear-
ance by tumor specific cytotoxic T lymphocytes (CTL) and natural 
killer (NK) cells. A major pathway responsible for CTL and NK 
cell mediated apoptosis is the Fas-Fas ligand (FasL) system. When 
CTLs or NK cells recognize target cells, they become activated and 
express FasL, which binds to Fas receptors on the surface of target 
cells and induces their apoptosis.26 Cancer cells frequently display 
decreased sensitivity to apoptotic stimuli, and previous studies have 
linked Shh signaling to cell survival in some experimental systems. 
We found that Shh expression protects PDECs from a caspase 8- and 
caspase 3-dependent apoptotic pathway (Fig. 1A). This protective 
effect of Shh appears to be mediated in part through the stabilization 
of the anti-apoptotic proteins Bcl-2 and Bcl-XL. This is consistent 
with previous observations that Hedgehog signaling can enhance 
Figure 1. Shh protects PDECs from Fas‑induced apoptosis. (A) Trp53 null, Ink4a/Arf null 
PDECs infected with either Shh or GFP were plated out at a density of 1 x 106 cells per well, 
and allowed to attach. Cells were pretreated with inhibitors of caspase 3 or 8 (20 mM) for 
1 hour, as indicated, then treated with 100 mM cycloheximide, or vehicle for a period of 24 
hours. (B) Trp53 null, Ink4a/Arf null PDECs and infected with either Shh GFP were plated out 
at a density of 1 x 106 cells per well, and allowed to attach. Cells were pretreated for 1 hour 
with anti‑FasL antibody (MFL3) as indicated, and then treated with 100 mM cycloheximide, or 
vehicle for a period of 24 hours. Cells were harvested and counted and viability assessed by 
trypan blue exclusion.
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levels of Bcl-2 in basal cell carcinoma cell lines and medulloblastoma 
cells, although in these studies transcriptional activation of Bcl-2 
was observed.27-29 Activation of caspases 8 and 3 is associated with 
death receptor-induced apoptosis,30 and previous data have shown 
that Shh expression is able to rescue cells from apoptosis mediated 
by the Fas death receptor.31 Furthermore, apoptosis mediated by the 
Shh pathway inhibitor cyclopamine, requires Fas: FasL interaction,32 
and cyclopamine treatment upregulates Fas expression in BCC cell 
lines, while expression of activated Smo inhibits Fas expression in 
these cells.32 We showed using blocking antibodies, that inhibiting 
Fas: FasL interaction protects PDECs from apoptosis (Fig. 1B), 
implicating the Fas pathway in apoptosis in PDECs, and indicating 
a role for Shh in protecting PDECs from death receptor mediated 
apoptosis.
Our findings are of particular interest given the potential role 
of Fas signaling in pancreatic cancer. Prior studies have shown 
that pancreatic cancer cells express the death receptors Fas, TRAIL 
and TNF-R but are strongly resistant to death receptor-induced 
apoptosis, possibly due to over-expression of the anti-apoptotic 
proteins Bcl-2 and Bcl-XL.
33 This is also interesting in light of our 
recent finding that Shh signaling in pancreatic duct cells can lead to 
stabilization of Bcl-2 and Bcl-XL in response to apoptotic stimuli.
21
Previous work has shown that many pancreatic cancers and 
pancreatic cancer cell lines lose expression or function of Fas,34,35 
and the loss of Fas has been shown to correlate with extra-pancreatic 
spread and shorter overall survival in PDAC patients.35 Perhaps more 
intriguingly, Fas ligand is frequently expressed in human PDAC 
and pancreatic cancer cell lines, but is not expressed in the normal 
adult pancreas.34 This combination of events may provide PDACs 
with a degree of protection from the immune response. FasL is 
expressed not only by immune cells, but also on nonlymphoid cells 
in organs where an inflammatory reaction might cause damage, for 
example the eyes, brain and testes.36,37 In these organs, cell surface 
FasL expression induces apoptosis in infiltrating pro-inflammatory 
cells.36,37 Several studies have now shown that certain tumors may 
also be sites of immune privilege.38 A variety of cancer cell lines have 
been shown to induce apoptosis in Fas-expressing lymphoid cells in 
vitro, and there is growing evidence to suggest that a similar situation 
may exist in vivo.38 For example, down-regulation of FasL expression 
in colon tumor cells significantly reduced tumor development in 
syngeneic immunocompetent mice, and led to increased lymphocyte 
infiltration.39 Our data raise the possibility that Shh signaling can 
render pancreatic cancer cells insensitive to Fas-mediated apoptosis, 
thus allowing protection from infiltrating T cells, and enabling a 
counter-attack against tumor-reactive immune cells (Fig. 2). If this 
is the case, immune based therapeutic strategies such as adoptive 
T cell therapy or cancer vaccines would not be predicted to be 
efficacious. Novel approaches to therapeutic intervention might aim 
to neutralize this counterattack or re-establish tumor cell sensitivity 
to Fas.
shh And K-rAs In PAnCreAtIC tuMor ForMAtIon  
And ProgressIon
Activating K-Ras mutations are one of the most frequent 
genetic alterations associated with pancreatic cancers, detected 
in over 90% of all pancreatic adenocarcinomas. We found that 
orthotopic transplantation of K‑Ras-infected PDECs lacking either 
Ink4a/Arf or Ink4a/Arf and Trp53 leads to the development of 
undifferentiated carcinomas within sixty days of transplant.21 This 
is in contrast to our finding that transplantation of Shh-infected 
PDECs induces early atypical ductal lesions within the pancreas that 
fail to progress further within 120 days.21 However in vitro, Shh 
stimulates proliferation to a similar extent as activated K-Ras in cells 
lacking the Trp53 and Ink4a/Arf tumor suppressor loci.21
This enhanced ability of activated K-Ras, compared with Shh, to 
transform PDECs is of great interest given that cells of each genotype 
proliferate at a similar rate, and exhibit activation of the signaling 
molecules Akt and Erk1/2. The increased capacity for transformation 
by K-Ras may reflect an enhanced survival advantage. Alternatively, 
it may reflect the activation of the Ral signaling pathway by K-Ras, 
but not Shh, as previous studies in other experimental systems 
have shown that activation of the Ral signaling pathway principally 
mediates the transforming properties of activated Ras proteins.40,41 
Analysis of the activation status of this, and other, signaling pathways 
in Ras-expressing PDECs compared with Shh-expressing PDECs 
should provide additional insights into the mechanisms impor-
tant for pancreatic cancer development, and further, may identify 
potential therapeutic targets.
However, we have found that Shh cooperates with activated 
K-Ras in the initiation and maintenance of pancreatic tumors.21 Shh 
enhanced tumor initiation by K-Ras, and increased tumor volume. 
Similar findings were made in a model of PDAC induced by a 
constitutively active Gli2 allele.25 Investigation of cell lines isolated 
from tumors induced by either K-Ras alone or Shh and K-Ras 
revealed that cells derived from K-Ras-expressing tumors were highly 
sensitive to inhibition of the MAP kinase and Akt/mTOR signaling 
pathways, while cell lines expressing both K-Ras and Shh continued 
to proliferate despite inhibition of these signaling pathways.21 
Furthermore, simultaneous inhibition of these pathways failed to 
induce complete arrest in cells expressing K-Ras and Shh. However, 
Shh pathway inhibition, using either cyclopamine or Smo-targeting 
shRNAs, coupled with PI3K pathway inhibition led to growth 
arrest and cell death. Thus, these data indicate that Shh signaling in 
pancreatic cancer cells can reduce the requirement of tumor cells for 
oncogenic Ras.
Figure 2. Model for immune privilege in Shh‑expressing pancreatic tumor 
cells. Shh‑expressing pancreatic tumor cells are resistant to Fas‑mediated 
apoptosis and therefore protected from immune attack by Fas ligand 
(FasL)‑bearing infiltrating T cells. Pancreatic tumors may also be a site of 
immune privilege: upregulation of FasL on the surface of pancreatic tumor 
cells enables the tumor to counterattack Fas‑bearing T cells, inducing 
Fas‑mediated apoptosis.
www.landesbioscience.com Cell Cycle 1555
Shh Signaling and Pancreatic Cancer
The data demonstrate the sustained requirement for multiple 
Ras signaling pathways in tumor maintenance. This is in contrast 
with previous studies that have suggested that Ras transformed 
cells are dependent only on the sustained activation of the PI3K / 
Akt pathway.41 These findings also suggest that constitutive Shh 
pathway activation can reduce the dependence of tumor cells on 
activated K-Ras. This discovery is important since it suggests that 
pancreatic ductal tumors with activated Shh signaling will be resistant to 
inhibition of Ras-regulated signaling pathways. Pharmacological 
inhibition of Ras signaling pathways has been proposed as a thera-
peutic strategy for PDAC, and several drugs that target Ras-regulated 
signaling pathways are already in development and in clinical trials. 
Given our results, further investigation in vivo using different models 
induced by a variety of genetic lesions, including Shh signaling, may 
be required to identify the conditions under which these compounds 
will provide therapeutic benefit in PDAC.
Investigation of cell lines also showed that inhibition of the 
hedgehog signaling molecule smoothened by shRNA or the 
antagonist cyclopamine, in cell lines expressing only K-Ras, induced 
complete cell death, suggesting that K-Ras stimulates the hedgehog 
signaling pathway, and further, that these cells remain dependent 
on a hedgehog-mediated signal for survival, in the absence of addi-
tional stimulation of the pathway.21 Curiously, cell lines expressing 
both K-Ras and Shh do not undergo apoptosis following inhibition 
of Shh signaling, and continue to grow albeit at a reduced rate. 
Thus, inhibition of the Shh pathway might not be an effec-
tive treatment in tumors in which Shh signaling is activated in a 
K-Ras-independent manner.
In Ras-induced tumors, low level Shh 
pathway activation must occur at the level 
of smoothened, or further upstream, since 
cell lines from these tumors are sensitive 
to inhibition of this molecule. However, 
cell lines from Ras-induced tumors with 
additional Shh signaling are less sensitive to 
pathway inhibition. This observation raises 
the possibility that Shh pathway activation 
may be qualitatively different in cells with 
Ras-activated Shh signaling, compared with 
cells ectopically expressing Shh. In addi-
tion, we cannot discount the possibility that 
Ras signaling also affects the Shh pathway 
further downstream. In fact, new evidence 
suggests that in cancer cells, MAPK and 
Akt signaling may regulate the nuclear 
localization and transcriptional activity 
of Gli1,42 while in cultured fibroblasts 
Akt activation is able to potentiate Gli 
activation by low level Shh signaling.43,44 
We have shown that Shh can stimulate the 
MAPK and PI3K/Akt pathways. Perhaps a 
positive feedback loop exists by which Shh 
signaling stimulates the MAPK and Akt 
pathways, while MAPK and Akt signaling 
can also stimulate Shh signaling at the level 
of the Gli transcription factors, reinforcing 
the activation of the pathway (Fig. 3). Thus, 
the K-Ras and Shh signaling pathways may 
synergize during pancreatic tumorigenesis 
in vivo.
Collectively, the above findings indicate that there is substan-
tial cooperation and cross signaling between Ras and Shh 
pathways. Delineating how hedgehog signaling is activated in PDAC, 
and how Shh signaling and Ras signaling interact, is crucial before 
attempting to antagonize either pathway as a therapeutic strategy.
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